Barclays raised the firm’s price target on Exelixis (EXEL) to $40 from $29 and keeps an Equal Weight rating on the shares. The firm updated the company’s model to reflect a higher probability of sucess in colorectal cancer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Pan-Tumor Rollover Study: A New Horizon in Cancer Treatment
- RBC downgrades Exelixis on valuation ahead of Cabometyx cliff
- Exelixis downgraded to Sector Perform from Outperform at RBC Capital
- Truist biotech analyst holds an analyst/industry conference call
- Exelixis price target raised to $53 from $47 at H.C. Wainwright